Airway Therapeutics was created in 2011 as a spin-out of Cincinnati Children’s Hospital Medical Center (CCHMC). Our goal is to bring innovation and expertise in protein therapeutics development for applications in the lung and pediatrics disciplines.
We are committed to offering innovative solutions for serious and often rare, lung conditions and look forward to working closely with FDA and EMA to facilitate the development of AT-100.
Each member of Airway’s management team brings more than 20 years of experience in academic and industrial research and development, drug development for rare diseases, along with experience in bringing development products to market.
Marc Salzberg, MD
President & Chief Executive Officer
Marc has more than 20 years of academic and pharmaceutical experience in the management of drug development and clinical research. He spent several years at Roche’s headquarters in Basel, Switzerland as well as its affiliate in Toronto, Canada. As Head of Clinical Cancer Research at the Basel University, he co-founded and managed a clinical research network in Switzerland (CCRC). Marc was also a founder and President of Pharma Brains, a European boutique CRO, which has been acquired by Medpace, a US based global CRO, after 10 years of successful growth under Marc’s leadership. Marc then served as Vice President of Medical Affairs at Medpace. Marc earned his Medical Doctorate degree from the University of Basel, Switzerland. His medical training and practice includes pediatrics/neonatology.
Paul Kingma, MD, PhD
Chief Medical Officer
Prior to becoming CMO, Paul was a member of our Scientific Advisory Board and has been instrumental in supporting Airway with the development of the AT-100 formulation, analytical assays and animal experiments. Since 2001, his focus on research and clinical includes SP-D and its role in the pathogenesis of lung diseases, particularly in neonates, the development of the preterm lung and bronchopulmonary dysplasia (BPD). He is the Neonatal Director at the Cincinnati Fetal Center, Co-Director of the Cincinnati Bronchopulmonary Dysplasia Center, Attending Neonatologist at Cincinnati Children’s Hospital and Associate Professor of Pediatrics in the UC Department of Pediatrics. Paul received his PhD in Biochemistry and his MD from Vanderbilt University in 2000. He completed his residency and fellowship training at Cincinnati Children’s Hospital Medical Center.
Alan S. Wolk
Chief Financial Officer
Alan has 30 years of finance and general management experience in Dupont and Invista, a subsidiary of Koch Industries. He held senior executive positions including President, Interiors, a $2B+ business in both Dupont and Invista. Previously, Alan was CFO, Dupont Nylon, a $6.5B segment. Alan led global businesses with region leading sales and manufacturing operations in NA, China and Europe. Earlier, Alan was CFO of Dupont Pharmaceuticals and Diagnostics. He led successful M&A and divestiture projects, for example, buying businesses in Germany and China and playing a leadership role in Dupont’s acquisition of ICI Textiles, joint venturing of Dupont’s Pharma business with Merck, and selling the Virology business to Ortho. Since leaving Invista, Alan has taught Finance at University of Georgia Terry College of Business. Alan has an MBA with a concentration in Finance from Temple University in Philadelphia.
Paul V. Remsen
Senior Vice President, CMC
Paul has more than 20 years experience in commercial and clinical manufacturing of recombinant proteins. As Director of Manufacturing at Genzyme, Paul led commercial purification of Cerezyme as the company began remediation of the Allston Landing plant under Consent Decree. Paul managed all aspects of clinical manufacturing at MedImmune’s Gaithersburg Pilot Facility and at Amgen Rhode Island managed large-scale commercial purification of Enbrel in the company’s state-of-the-art BioNext facility. Paul also served as Senior Director of Clinical Manufacturing at Regeneron Pharmaceuticals and was responsible for early clinical production of Arcalyst and Eylea. Paul holds a Bachelor’s degree in Biology from the State University of New York at Binghamton.
Uday Patel, RAC (US, EU)
Vice President - Regulatory Affairs & Quality Assurance
Uday is an accomplished biopharmaceutical professional with over twenty-five years of broad-based experience covering all aspects of biopharmaceutical clinical development. Uday has been a partner and key member of senior management and scientific project teams in successful start-ups to clinical stage organizations. Uday’s background includes global experience in program management, clinical operations, regulatory affairs, analytical development and quality assurance. In various positions at Femasys, Vaxart, Aviragen Therapeutics, Inhibitex and Peptimmune, he was responsible for development and implementation of regulatory strategy for multiple clinical programs and management of QA tasks in clinical development of infectious disease therapies (viral and bacterial infections), vaccine therapies, autoimmune indications and medical devices. He also held several positions at Biopure and Altus Pharmaceuticals in the Quality and Analytical functions. Uday holds a Bachelor’s degree in Biochemistry from Suffolk University and a Master’s degree in Biology from Harvard University.
Jeffrey A. Whitsett, MD is Professor of Pediatrics, Chief of the Section of Neonatology, Perinatal and Pulmonary Biology, and Executive Director of the Perinatal Institute at Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine. Dr. Whitsett received his B.A. from Colgate University and his medical degree from Columbia University. He trained in Pediatrics at Mt. Sinai Hospital, New York City and in Neonatal-Perinatal Medicine at the Children’s Hospital Medical Center, University of Cincinnati College of Medicine. Following his fellowship, he joined the faculty at the University of Cincinnati College of Medicine in 1977 and since has risen through the ranks to Professor. He is internationally known for his research in pulmonary medicine, as well as for his clinical expertise in neonatology. Dr. Whitsett has made a series of groundbreaking contributions in pulmonary medicine and biology in his studies of the surfactant proteins A, B, C and D, cloning their genes and clarifying their roles in lung development and function. Throughout his career, Dr. Whitsett has transitioned from molecular biology to animal models and then to the diagnosis and therapy of human disease. Importantly, he has played a critical role in making surfactant protein replacement routine in the treatment of immature lungs and respiratory distress syndrome in premature infants. Notably, his laboratory has contributed to the identification of a number of genes critical for lung formation and function and shown that mutations in genes regulating surfactant homeostasis are responsible for acute and chronic lung disease in infants and adults. Dr. Whitsett is the author of over 500 papers in both the basic science and clinical literature.
Dr. Whitsett is a member of the National Academy of Medicine and the recipient of various awards, including the Mead Johnson Award, a National Institutes of Health (NIH) Merit Award, the William Cooper Procter Award from Cincinnati Children’s, the Amberson Lecture Award of the American Thoracic Society, the prestigious Daniel Drake Medal for scientific contributions from the University of Cincinnati College of Medicine, the highly respected Arvo Ylppö Medal Award from Finland, the Grand Hamdan International Award on Neonatal Medicine from the United Arab Emirates, 2015 Avery Award, a joint award of the SPR/APS honoring Mary Ellen Avery, American Academy of Pediatrics 2015 Virginia Apgar Award. Columbia University P&S Alumni Gold Medal Award, and the 2018 Edward Livingston Trudeau Medal from the American Thoracic Society.
Paul Kingma, MD, PhD
Dr. Kingma’s research investigates lung growth and injury in premature infants and the role of the innate immune system in pulmonary injury. Paul has lead numerous clinical and basic science studies and has been researching the biological activity and therapeutic potential of surfactant protein-D since 2001. Specific projects currently focus on the role of surfactant protein-D in neonatal sepsis and lung injury and on MRI-based evaluation of bronchopulmonary dysplasia and lung growth. He is the Neonatal Director at the Cincinnati Fetal Center, Co-Director of the Cincinnati Bronchopulmonary Dysplasia Center, Attending Neonatologist at Cincinnati Children’s Hospital and Associate Professor of Pediatrics in the UC Department of Pediatrics. Paul received his PhD in Biochemistry and his MD from Vanderbilt University in 2000. He completed his residency and fellowship training at Cincinnati Children’s Hospital Medical Center.
Ola Saugstad, MD, PhD, University of Oslo
Ola Didrik Saugstad is Professor Emeritus of Pediatrics and Director of the Department of Pediatric Research University of Oslo, Consultant of Neonatology, Oslo University Hospital, Rikshospitalet. He is an adjunct professor of Pediatrics at Northwestern University, Chicago. He has published Published more than 400 articles—374 articles in peer reviewed journals—and of those, 36 are recorded in Pubmed. His field of interests are newborn oxygenation and resuscitation, oxidative stress and lung injury. Dr. Saugstad has served in supervisory and teaching roles with PHD students and has given over 300 lectures at international congresses and Universities. His numerous awards and honors include the AAP: The Landmark Award 2012, the Nordic Medal Award, 2011 and an honorary professorship from Moscow University in 2013.
Maximo Vento, MD, PhD, Univ. of Valencia
Dr. Vento presently holds a number of positions including: Professor of Pediatrics (since 1993) at the University of Alicante; Chief of the Division of Neonatology (since 2005); University & Polytechnic Hospital La Fe.; Director of the Neonatal Research Unit (since 2005) at The Health Research Institute La Fe. He is also President of the Spanish Neonatal Society (SEN) and National Coordinator of the Spanish Network for Maternal and Infant Health and Development (Red SAMID) pertaining to the INSTITUTO CARLOS III (Spanish Ministry of Economy and Competitiveness). In 2017, he has been appointed Chairman of the European Board of Neonatology and Member of the Executive Committee of the European Society for Pediatric Research.
His academic honors and activities began with advanced degrees from the University of Valencia starting in 1975, and have included numerous featured speaking engagements at over 80 National and International Congresses of the Neonatal Societies and Research Symposium. Max diverse lines of research and interests have included areas of general neonatal care; Physiology of the Fetal to Neonatal transition; Perinatal Asphyxia; Resuscitation in the Delivery Room; Oxygen: physiology, hypoxia/hyperoxia derived toxicity, oxidative and nitrosative stress and biomarkers; Redox Regulation; microbiome/infection/genome wide expression. His presence among national and international journals have added up to well over 350 speaking and published works.
John is a co-founder and Managing Partner of Triathlon Medical Ventures based in Cincinnati and Executive in Residence at CincyTech. He has 25 years of venture investing and 13 years of research and R&D management experience in biomedical science. John was a Managing Director of Senmed Medical Ventures from 1989 until 2003. Previously, John spent 13 years with Battelle Memorial Institute serving in various research, research management, and business development capacities. John is a member of the Boards of Aerpio Therapeutics, Eccrine Systems, and Chaiman of Airway Therapeutics. He is an observer on the board of CoLucid Pharmaceuticals and and has served previously on the boards of Akebia (AKBA) (Founder and Chairman), Kereos, Syntherix, CS-Keys and as an obvserver at Endocyte (ECYT). John is a member of the board of the Global Cardiovascular Innovation Center at the Cleveland Clinic, Chairman of the Investment Advisory Board of the Harrington Discovery Institute, Innovation Fund Board at Children’s Hospital Medical Center, and the Board of Trustees of Edison Biotechnology Institute of Ohio University. John earned BS, MS and PhD degrees in Microbiology and Virology from The Ohio State University.
Marc Salzberg, MD
Marc has more than 20 years of academic and pharmaceutical experience in the management of drug development and clinical research. He spent several years at Roche’s headquarters in Basel, Switzerland as well as its affiliate in Toronto, Canada. As Head of Clinical Cancer Research at the Basel University, he co-founded and managed a clinical research network in Switzerland (CCRC). Marc was also a founder and President of Pharma Brains, a European boutique CRO, which has been acquired by Medpace, a US based global CRO, after 10 years of successful growth under Marc’s leadership. Marc then served as Vice President of Medical Affairs at Medpace. Marc earned his Medical Doctorate degree from the University of Basel, Switzerland
His medical training and practice includes pediatrics/neotology and oncology.
Margaret K. Hostetter, MD
Margaret K. Hostetter, MD is the Chair of the Department of Pediatrics at the University of Cincinnati and the Director of the Research Foundation at Cincinnati Children’s Hospital Medical Center (CCHMC). In this capacity, she has responsibility for clinical programs and research investments across CCHMC. With Mark Mumford, she oversees Cincinnati Children’s Innovation Ventures (formerly the Center for Technology Commercialization). She has held continuous funding from the National Institutes of Health since 1985 and has served on research review committees for the Howard Hughes Medical Institute, the March of Dimes (chair), the Burroughs Wellcome Foundation (chair), and numerous NIH study sections. She is a member of the National Academy of Medicine and other research
organizations. Prior to joining Cincinnati Children’s, Peggy was chair of the Department of Pediatrics at Yale. She obtained her BA degree from Denison University and her MD degree from Baylor College of Medicine.
Mike Venerable is Managing Director at CincyTech, a Cincinnati-based seed stage venture investment company. Since 2007 CincyTech has invested in 54 seed-stage companies in therapeutics, diagnostics, medical devices, software applications, wearables and consumer products. He leads CincyTech’s investment process, working directly with founders to capitalize and build high potential technology companies in Southwest Ohio. He joined CincyTech after returning to Ohio after a 20-year entrepreneurial career in the Washington, DC region, where he cofounded and sold a big data consulting business after working at Oracle and Booz Allen and Hamilton. Earlier he spent four years in the US Army as a Korean linguist and attended the University of Dayton.
AIRWAY represents an interesting investment opportunity for the following reasons: